Feasibility of intracoronary nicorandil for inducing hyperemia on fractional flow reserve measurement: Comparison with intracoronary papaverine.
Coronary hyperemia
Fractional flow reserve
Nicorandil
Journal
International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291
Informations de publication
Date de publication:
01 09 2020
01 09 2020
Historique:
received:
18
01
2020
revised:
22
03
2020
accepted:
04
05
2020
pubmed:
11
5
2020
medline:
15
5
2021
entrez:
11
5
2020
Statut:
ppublish
Résumé
Adenosine and adenosine triphosphate (ATP) are widely used to induce hyperemia for fractional flow reserve (FFR) measurements. Caffeine attenuates their hyperemic effects, but not those of nicorandil and papaverine. No studies have systematically compared the hyperemic efficacies of nicorandil, papaverine, and ATP with and without caffeine abstention. FFRs were measured using nicorandil 2 mg (FFR In group 1, FFR Nicorandil 2 mg is a safe and practical alternative for patients who consume caffeine-containing products before the test or have contraindications for adenosine/ATP. Increasing the nicorandil dose to 4 mg or administering adjunctive nicorandil during ATP infusions does not offer any clinical advantages compared with administering nicorandil 2 mg alone.
Sections du résumé
BACKGROUND
Adenosine and adenosine triphosphate (ATP) are widely used to induce hyperemia for fractional flow reserve (FFR) measurements. Caffeine attenuates their hyperemic effects, but not those of nicorandil and papaverine. No studies have systematically compared the hyperemic efficacies of nicorandil, papaverine, and ATP with and without caffeine abstention.
METHODS
FFRs were measured using nicorandil 2 mg (FFR
RESULTS
In group 1, FFR
CONCLUSIONS
Nicorandil 2 mg is a safe and practical alternative for patients who consume caffeine-containing products before the test or have contraindications for adenosine/ATP. Increasing the nicorandil dose to 4 mg or administering adjunctive nicorandil during ATP infusions does not offer any clinical advantages compared with administering nicorandil 2 mg alone.
Identifiants
pubmed: 32387252
pii: S0167-5273(20)30097-8
doi: 10.1016/j.ijcard.2020.05.013
pii:
doi:
Substances chimiques
Vasodilator Agents
0
Nicorandil
260456HAM0
Papaverine
DAA13NKG2Q
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-6Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors have no conflicts of interest to declare.